Document Detail

Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly.
MedLine Citation:
PMID:  23198869     Owner:  NLM     Status:  Publisher    
Background  DAV-interferon (IFN)-β therapy is a combination chemotherapy of dacarbazine (DTIC), nimustine (ACNU) and vincristine (VCR) with local subcutaneous injection of IFN-β that is widely employed as postoperative adjuvant chemotherapy to treat malignant melanoma in Japan. However, the efficacy of DAV-IFN-β therapy has not been confirmed by randomized controlled trials and the benefit of DAV-IFN-β therapy has not been established yet. This study evaluated the contribution of DAV-IFN-β therapy to improve survival of postoperative patients with cutaneous melanoma. Methods Patients with stage II or III cutaneous melanoma seen at Nagoya University Hospital from January 1998 to December 2009 were eligible for this study. Disease-free survival rates and melanoma-specific survival rates were evaluated. A propensity score was calculated to control for the effects of variables related to decisions regarding the application of DAV-IFN-β therapy. Results  Eighty-two stage II and 60 stage III melanoma patients were included. In the post-matched stage II patients (17 matched pairs), the mean (±SE) disease-free survival rates were 39.9±13.7% for DAV-IFN-β therapy and 73.1±11.7% for non-use (hazard ratio for recurrence, 2.06; 95% CI, 0.63-6.69; P = 0.23), and the melanoma-specific survival rates were 66.2±20.0% for DAV-IFN-β therapy and 86.2±9.1% for non-use (hazard ratio for death, 1.09; 95% CI, 0.17-6.82; P = 0.93). In the post-matched stage III patients (nine matched pairs), the disease-free survival rates were 29.6±16.4% for DAV-IFN-β therapy and 33.3±15.7% for non-use (0.69; 95% CI, 0.22-2.17; P = 0.53), and the melanoma-specific survival rates were 55.6±16.6% for DAV-IFN-β therapy and 44.4±16.6% for non-use (0.67; 95% CI, 0.18-2.50; P = 0.55). Conclusions  DAV-IFN-β therapy brought no significant improvement in either disease-free survival rates or melanoma-specific survival rates of patients with stage II or III cutaneous melanoma. A randomized controlled trial would be required to further evaluate the efficacy of DAV-IFN-β therapy as an adjuvant chemotherapy.
T Matsumoto; K Yokota; M Sawada; A Sakakibara; S Shibata; S Yasue; Y Tomita; H Yatsuya; M Akiyama
Related Documents :
24135679 - Early stage papillary serous or clear cell carcinoma confined to or involving an endome...
9471059 - Chronic lymphocytic leukemia treatment.
17545799 - Second line therapies for the treatment of gastrointestinal stromal tumor.
24682439 - Biologic therapy response and drug survival for females compared to males with rheumato...
24224689 - Recurrence of gastroesophageal reflux disease is correlated with a short dinner-to-bedt...
24559449 - Sentinel lymph node biopsy in melanoma: controversies and current guidelines.
24764679 - Clinicopathological features and trend changes of gastric carcinoma in southern china.
9111169 - Mode of disease progression in primary myelodysplastic syndromes: a japanese co-operati...
3940069 - Prognostic factors in primary cutaneous malignant melanoma.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-1
Journal Detail:
Title:  Journal of the European Academy of Dermatology and Venereology : JEADV     Volume:  -     ISSN:  1468-3083     ISO Abbreviation:  J Eur Acad Dermatol Venereol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9216037     Medline TA:  J Eur Acad Dermatol Venereol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology.
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan Department of Public Health and Health Systems, Nagoya University Graduate School of Medicine, Nagoya, Japan Department of Public Health, Fujita Health University, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinoma...
Next Document:  Construction of plastid reference proteomes for maize and Arabidopsis and evaluation of their orthol...